

Chronic Lymphocytic Leukaemia Patients

Reference Number: RDF1489-23

Date of Response: 24/05/23

Further to your Freedom of Information Act request, please find the Trust's response(s) below:

Please be aware that the Royal Devon University Healthcare NHS Foundation Trust (Royal Devon) has existed since 1st April 2022 following the integration of the Northern Devon Healthcare NHS Trust (known as Northern Services) and the Royal Devon and Exeter NHS Foundation Trust (known as Eastern Services).

Dear Royal Devon University Healthcare NHS Foundation Trust,

I have a Freedom of Information request that I would like to raise.

- 1. How many patients has your Organisations treated in the past 3 months for Chronic Lymphocytic Leukaemia (CLL)?*

Answer: 77 patients on systemic anti-cancer treatment (SACT) treatments only.

- 2. In case you do not treat CLL, which other Organisation do you refer patients needing treatment to?*

Answer: Not applicable.

- 3. How many Chronic Lymphocytic Leukaemia (CLL) patients have been treated in the past 3 months with the following:*

Answer: Please see table below. In accordance with Section 40 (2) of the Freedom of Information Act 2000, we are unable to provide figures where the number of patients is less than or equal to five and could risk the identification of those patients and breach Caldicott principles. In these cases ≤ 5 is used to indicate that a figure between 1 and 5 is being suppressed.

This follows NHS Digital (formerly HSCIC) analysis guidance (2014) which states that small numbers within local authorities, wards, postcode districts, CCG's providers and Trusts may allow identification of patients and should not be published.

	*Total
<i>BR (bendamustine + rituximab)</i>	Nil
<i>Calquence (acalabrutinib)</i>	32
<i>FCR (fludarabine + cyclophosphamide + rituximab)</i>	≤ 5
<i>Gazyva (obinutuzumab) + chlorambucil</i>	≤ 5
<i>Imbruvica (ibrutinib)</i>	21
<i>Venclexta (venetoclax)</i>	12
<i>Venclexta (venetoclax) + Gazyva (obinutuzumab)</i>	8
<i>Venclexta (venetoclax) + rituximab</i>	≤ 5

<i>Zydelig (idelalisib) + rituximab</i>	Nil
<i>Any other systemic anti-cancer therapy</i>	Nil
<i>Wait and watch (monitoring only, no active treatment)</i>	We do not hold this information

**Data from most recent national SACT submission – December 2022 to February 2023. Systemic anti-cancer treatment (SACT) treatments only.*

4. *If your Organisation does treat Chronic Lymphocytic Leukaemia patients, do you currently participate in any ongoing clinical trials for the treatment of CLL?*

Answer: Yes.

5. *If so, can you please provide the name of each trial along with the number of patients taking part?*

Answer: FLAIR: Front-Line therapy in CLL: Assessment of Ibrutinib + Rituximab. Number of patients taking part = 17.